BCR-ABL kinase domain mutations in patients with CML, which confer resistance to the tyrosine kinase inhibitor imatinib21, are well-characterized examples for this mechanism. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.